The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
CIO News
£1.7 million for vaccine to prevent lung cancer
2 April 2024
Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
What's new for Oxford Cancer
-
New study reveals how T cells gain and maintain tolerance to gut bacteria
10 April 2024
-
University of Oxford Lung cancer trial reaches 400 participants
7 April 2024
-
£9m to Oxford for the Next Generation of Cancer Experts
3 April 2024
-
OCION: In conversation with Tim Elliott
28 March 2024
-
£1.7 million for vaccine to prevent lung cancer
22 March 2024